Abstract
Abstract Background: Alterations of intestinal microbiota may play a role in the pathogenesis of psoriasis. Dysbiosis may cause disruption of the intestinal barrier, which contributes to immune activation by translocation of microbial antigens and metabolites. Intestinal fatty acid-binding protein (I-FABP) serves as a biomarker of enterocyte damage. Purpose: The aim of this study was to investigate serum concentration of I-FABP in patients with psoriasis. Methods: A cross-sectional hospital-based study on fifty psoriatic patients and thirty-five age and sex-matched healthy volunteers as a control group were enrolled in the study, serum I-FABP concentration was measured using an enzyme-linked immunosorbent assay. Results: Concentration of serum I-FABP was higher in patients compared to controls (P = 0.04). The serum level of I-FABP was higher in patients with skin phototype IV than in those with skin phototype III (P = 0.040). There were significant positive statistical correlations between I-FABP with age and disease duration. Conclusion: I-FABP, a biomarker for gut permeability, is increased in psoriasis and correlates with disease duration and age. Further investigations are needed to determine whether reinforcing intestinal barrier may be a new therapeutic target in psoriasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
